Premium
Carbapenem‐resistant Acinetobacter baumannii infections after organ transplantation
Author(s) -
Reddy P.,
Zembower T.R.,
Ison M.G.,
Baker T.A.,
Stosor V.
Publication year - 2010
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/j.1399-3062.2009.00445.x
Subject(s) - acinetobacter baumannii , medicine , intensive care medicine , pathogen , acinetobacter , carbapenem , organ transplantation , drug resistance , transplantation , antibiotics , microbiology and biotechnology , pseudomonas aeruginosa , immunology , bacteria , biology , genetics
P. Reddy, T.R. Zembower, M.G. Ison, T.A. Baker, V. Stosor. Carbapenem‐resistant Acinetobacter baumannii infections after organ transplantation.
Transpl Infect Dis 2010: 12: 87–93. All rights reserved Abstract: Multi‐drug resistant (MDR) gram‐negative infections among solid organ transplant (SOT) recipients have long been associated with high morbidity and mortality. Acinetobacter baumannii has emerged as a potent nosocomial pathogen with the recent acquisition of resistance to broad‐spectrum β‐lactams, aminoglycosides, fluoroquinolones, and most notably, carbapenems. Despite a national rise in carbapenem‐resistant A. baumannii (CRAB) infections, outcomes among SOT recipients with this emerging MDR pathogen are largely unknown. This single‐center cohort is the first to describe the characteristics, complications, and outcomes among abdominal organ transplant recipients with CRAB. The current study suggests that SOT patients with CRAB suffer from prolonged hospitalization, infection with other MDR organisms, allograft dysfunction and loss, and high overall infection‐related mortality.